Trinity Biotech (TRIB) announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Files Prospectus for $1 Million ADS Offering
- Trinity Biotech Reports Q3 2024 Financial Performance
- Trinity Biotech files to sell 650,000 American Depositary Shares for holders
- Trinity Biotech’s Q3 2024 Revenue and Strategic Growth
- Trinity Biotech reports Q3 EPS (46c) vs (88c) last year